Consistent lobbying, in combination with informed and respectful conversation, has resulted in a solution being found to the Myasthenia Gravis Community Request to have Rituximab listed as a PBS supported treatment for Myasthenia Gravis.
The MAA were keenly aided in this process by Rare Voices Australia (RVA). RVA CEO, Nicole Millis, navigated the pathways to making Government contact and to having our challenges understood. It was necessary for the MAA to illuminate the inadequacies in the current system. In this regard we very much thank the Pharmaceutical Benefits Advisory Committee for finding a pathway to achieving this outcome.
Rituximab treatment for people with Myasthenia will now be uniformly available through the PBS. Out of pocket expenses will be equitable to all patients. Gaining access will not depend on the depth of the private wallet or the particular hospital a patient attends. Clinician treatment choices will not be restricted with regard to this option.
During the past two years, many people, including a significant number of our Politicians, have taken the required time to hear the complicated issues and to support obtaining a positive outcome. Particular recognition is given to Health Minister Greg Hunt, Dr Mike Freelander MP and Trent Zimmerman MP.
The MAA would also like to recognise the contribution and support of our membership during this process and trust that many will benefit from this outcome.